Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer

18Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. They are more aggressive than other breast cancer subtypes, with a higher mean tumor size, higher tumor grade, the worst five-year overall survival, and the highest rates of recurrence and metastasis. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. In this review article, we review the efforts in developing targeted therapies for TNBC, discuss insights gained from these efforts, and highlight potential opportunities going forward. Accumulating evidence supports TNBCs as multi-driver cancers, in which multiple oncogenic drivers promote cell proliferation and survival. In such multi-driver cancers, targeted therapies would require drug combinations that simultaneously block multiple oncogenic drivers. A strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed.

Cite

CITATION STYLE

APA

Chapdelaine, A. G., & Sun, G. (2023, August 1). Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer. Biomolecules. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/biom13081207

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free